DRIVE is funded by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI aims to accelerate the development of better and safer medicines for patients.
The European Commission provides funding to IMI. Industry members contribute funding and/or in-kind resources to the specific IMI projects they are involved in. IMI has granted DRIVE a total of € 8.9 million in funding over a 5 years, with a mid-term evaluation.